https://t.co/U6zQA7uWHb. Come joint our lab Quezada Lab UCL Cancer Institute Cancer Research UK (CRUK) Cancer Research UK (CRUK) City of London Centre Great PhD opportunity to develop advanced immunotherapies against cancer
Congrats to Aurélien Marabelle’s team — intratumoural anti-CTLA-4 links Treg reduction with FcγR⁺ myeloid context, underscoring the FcγR landscape as a key determinant of CPI activity and translation. https://t.co/WdThERJRzy
Congratulations to @CharlesSwanton, Mariam Jamal-Hanjani and colleagues on their fascinating analysis of the evolution of lung cancer metastasis published in @Nature!
https://t.co/96aszH5GBW
Thrilled to see a new paper led by the outstanding @Brown_lab1, now out in Nature Biotechnology.
We provide mechanistic insights into how mRNA vaccines work. challenging key assumptions and offering new ways to control vaccine activity. (1/3)
Read here: https://t.co/zNZAGHJ9kd
Congrats to PICI researcher Dr. Catherine Wu of @DanaFarber on being part of the @CancerGrand ILLUMINE team, awarded $25M to explore the cancer dark proteome, research that could uncover entirely new targets for cancer treatment. https://t.co/B2DoF0KQTf
Excited to share our new work uncovering a previously unknown mechanism identifying ANKIB1 as the E3 ligase that writes a critical new letter of the ubiquitin code central for immune signalling: K11-linked ubiquitin https://t.co/B9BQpsaVeV
Huge thanks to the team at UCLH and the UCL Cancer Institute @ucl@uclh@uclcancer, particularly Elise Reese @ekvrees and Louise Ainley, and my mentors Benny Chain @BennyChain, Sergio Quezada @QuezadaLab and Kwee Yong.
Immunology takes center stage again at the #NobelPrize! Congratulations to Mary Brunkow, Fred Ramsdell & Shimon Sakaguchi for uncovering how regulatory T cells maintain immune tolerance—a discovery that transformed our understanding of autoimmunity and cancer immunotherapy
Are you looking for a Clinical Research Training Fellowship? Do you want join our team working in cancer immunology and immunotherapy? Check this great opportunity from @CRUKCOLcentre
https://t.co/AHeV3QjwSY
and contact our team to discuss our proposed project
Pleased to share our preprint describing a central role for post-transcriptional processes in the response to cancer immunotherapy. Huge amount of work led by Maria Vila de Mucha and @julia_hlond in collaboration with @QuezadaLab and @MartT_babraham 1/8
https://t.co/o5zDjBEC6X
🧬 Join us Friday 19th Sept for CART Autoimmunity Symposium in Central London 🧬 Guest speakers from Erlangen & Hamburg on latest developments in Lupus, Multiple Sclerosis, & MG. Register in link below & see you there! @uclh @uclcancer https://t.co/rww9s0PnS6
@Chrystal_Paulos What is the true activity of each of the many subsets of myeloid cells in tumours and can they be coordinated towards a single (tumour-targeting) activity?
Depletion of Tregs with a non-IL-2-blocking anti-CD25 enhanced antitumor responses in brain tumors and synergized with anti-PD-1 or a tumor antigen-targeted antibody https://t.co/FR8gfFbGn0 @uclcancer@QuezadaLab#Immunotherapy
CHIP is a common, age-related condition where mutated blood stem cells expand without causing blood disorders. CHIP raises the risk of hematological malignancies, chronic inflammatory diseases (like heart & lung disease), & lung cancer. This manuscript shows that CHIP somatic clones in blood���especially TET2 mutant ones—migrate into tumors, reshape immunity, drive progression, and promote recurrence. The ability of a somatic clonal expansion in the hematopoietic compartment, to regulate malignant progression in another tissue represents a new perspective in cancer biology. #CHIP #LCMS #cancer #biology #AACR25 https://t.co/EvOASp0Vi0
Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies: https://t.co/EB5a9vTrLO
Amazing collaboration led by @CR_UK funded @QuezadaLab @galvez_cancino @uclcancer and colleagues!